Frontiers3d
NAFLD treatment in diabetes: from current dietary interventions to novel treatment
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...
Frontiers11d
Inflammation-fibrosis interplay in inflammatory bowel disease: mechanisms, progression, and therapeutic strategies
Tumor Necrosis Factor-like Ligand 1A. Figure 3. Mechanistic diagram depicting how mesenchymal cells inhibit the development of intestinal fibrosis (By Figdraw). EVs, mesenchymal stromal cells secreted ...
Medindia14d
Asah1 Gene Identified as Potential Target for Treating Liver Disease
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...
Fox News14d
Lingering lung disorders 5 years post-COVID: Here's what to know
The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...
Times-News15d
DID IT FOR DILL: Dietrich wins 1A state championship for late coach
Slade Dill added to the illustrious history as top-seeded Dietrich routed No. 6 Challis 58-36 in the Idaho boys 1A state championship Saturday at the Ford Idaho Center in Nampa. “Seeing what he ...
Daily Herald15d
Girls basketball: Despite loss in Class 1A third-place game, St. Edward thrilled to end season at state
NORMAL — Cissna Park pulled away in the final minute of what had been a back-and-forth contest with St. Edward in the Class 1A third-place game, snapping a 44-44 tie by going 6 of 8 from the ...
SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...
WKRN-TV15d
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Its lead asset, SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trial and has shown promising Phase 1a and ... (NASH), with or without fibrosis.
Taiwan News15d
The Global Liver Fibrosis Treatment Market: Growth Trends and Opportunities
The primary causes of liver fibrosis include alcohol abuse, chronic hepatitis C virus (HCV) infection, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Despite ...
Armed robbery in Revesby15d
Researchers Identify Gene To Guide Novel Therapeutics Of Nonalcoholic Fatty Liver Diseases
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...
Science Daily17d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseases
About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...